Improving Immunotherapy Outcomes for Patients with Advanced NSCLC
Checkpoint inhibitor immunotherapy has revolutionized lung cancer treatment and ushered in a new era of scientific discovery that is focused on empowering our natural immune system
Checkpoint inhibitor immunotherapy has revolutionized lung cancer treatment and ushered in a new era of scientific discovery that is focused on empowering our natural immune system
Editor's Note: Post was updated on 10/21 with new recommendations and authorizations. There has been a lot of information recently about COVID-19 boosters and who should get them
Good mental health, or our emotional, psychological, and social well-being, is essential for overall health. Being diagnosed and living with cancer, however, can impact our mental
Flu vaccinations are the best way to help protect against the flu. Each year, the Centers for Disease Control and Prevention recommend that everyone 6 months of age and older
Small cell lung cancer (SCLC) accounts for about 15% of all lung cancers, and is found most often in people with a history of tobacco exposure. SCLC is an aggressive disease with
Coming to terms with a lung cancer diagnosis can be difficult. You might feel anxious, angry, or out of control. You might have difficulty sleeping or perhaps unable to even talk
In recent years, great strides have been made in understanding and treating lung cancer. While we’re excited to see these many developments, our priority at LUNGevity is to ensure
53 days after Julie Jones had video assisted thoracic surgery (VATS) to remove the lower lobe of her right lung, Julie ran a half marathon. Even more impressive, she finished only
On May 28, 2021, the global lung cancer community celebrated news that the US Food & Drug Administration (FDA) has granted accelerated approval for sotarasib as a second-line
According to the National Cancer Institute, approximately 70% of lung cancer patients are initially diagnosed with advanced-stage disease, which is more difficult to treat than
Approximately 23% of non-small cell lung cancer (NSCLC) have an EGFR-positive mutation. Advanced-stage NSCLC patients whose tumors have an EGFR mutation are often treated with one